Business Information
The group's principal activity is to develop safer and improved versions of widely prescribed drugs in large and growing markets. Utilizing proprietary carrierwave technology, the group is developing novel pharmaceuticals to address the significant drawbacks and adverse side effects of currently marketed drugs. The group's carrierwave technology can be applied in various ways to improve existing drugs. The group is in the development of three lead product candidates. The first product is nrp104, which is a prodrug of amphetamine. Nrp290, the second product candidate, is a prodrug of hydrocodone, an opioid widely used to treat acute pain. The third pipeline program is nrp369. This program is focused on developing a prodrug of oxycodone, an opioid widely used to treat chronic pain.
|
|
Name |
Title
|
Email
|
| Randal Kirk | Chmn., CEO, Pres., Principal Executive Officer | N/A | | Garen Manvelian | Chief Medical Officer, VP - Clinical - Regulatory Affairs | N/A | | John Thottathil | Chief Scientific Officer | N/A | | Krish Krishnan | Dir., CFO, COO | N/A | | Clifton Herndon | VP - Finance, Controller | N/A |
|
|
Year |
Sales |
Net Income |
| 2003 | N/A | (4,816) | | 2005 | N/A | (14,335) | | 2006 | N/A | (29,866)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
